Emerging therapeutic options in inflammatory bowel disease

Inflammatory bowel disease (IBD) is a chronic disease that requires chronic treatment throughout the evolution of the disease, with a complex physiopathology that entails great challenges for the development of new and specific treatments for ulcerative colitis and Crohn´s disease. The anti-tumor necrosis factor alpha therapy has impacted the clinical course of IBD in those patients who do not respond to conventional treatment, so there is a need to develop new therapies and markers of treatment response. Various pathways involved in the development of the disease are known and the new therapies have focused on blocking the inflammatory process at the gastrointestinal level by oral, intravenous, subcutaneous, and topical route. All these new therapies can lead to more personalized treatments with higher success rates and fewer relapses. These treatments have not only focused on clinical remission, but also on achieving macroscopic changes at the endoscopic level and microscopic changes by achieving mucosal healing. These treatments are mainly based on modifying signaling pathways, by blocking receptors or ligands, reducing cell migration and maintaining the integrity of the epithelial barrier. Therefore, this review presents the efficacy and safety of the new treatments that are currently under study and the advances that have been made in this area in recent years.     

Hirschsprung-associated inflammatory bowel disease: A multicenter study from the APSA Hirschsprung disease interest group

Background/PurposeA small number of Hirschsprung disease (HD) patients develop inflammatory bowel disease (IBD)-like symptoms after pullthrough surgery. The etiology and pathophysiology of Hirschsprung-associated IBD (HD-IBD) remains unknown. This study aims to further characterize HD-IBD, to identify potential risk factors and to evaluate response to treatment in a large group of patients.MethodsRetrospective study of patients diagnosed with IBD after pullthrough surgery between 2000 and 2021 at 17 institutions. Data regarding clinical presentation and course of HD and IBD were reviewed. Effectiveness of medical therapy for IBD was recorded using a Likert scale.ResultsThere were 55 patients (78% male). 50% (n = 28) had long segment disease. Hirschsprung-associated enterocolitis (HAEC) was reported in 68% (n = 36). Ten patients (18%) had Trisomy 21. IBD was diagnosed after age 5 in 63% (n = 34). IBD presentation consisted of colonic or small bowel inflammation resembling IBD in 69% (n = 38), unexplained or persistent fistula in 18% (n = 10) and unexplained HAEC >5 years old or unresponsive to standard treatment in 13% (n = 7). Biological agents were the most effective (80%) medications. A third of patients required a surgical procedure for IBD.ConclusionMore than half of the patients were diagnosed with HD-IBD after 5 years old. Long segment disease, HAEC after pull through operation and trisomy 21 may represent risk factors for this condition. Investigation for possible IBD should be considered in children with unexplained fistulae, HAEC beyond the age of 5 or unresponsive to standard therapy, and symptoms suggestive of IBD. Biological agents were the most effective medical treatment.Level of EvidenceLevel 4     

个体化健康教育对糖尿病抑郁症运动依从性影响

目的研究糖尿病并发抑郁症患者运动依从性的影响因素,探讨有效的干预措施。方法选择2018年11月-2019年8月天津市公安医院收治的糖尿病患者158例为研究对象,根据抑郁自评量表(CES-D)调查情况分为糖尿病抑郁(DDM)组和糖尿病非抑郁(NDDM)组各79例,采用问卷的形式分析个体化健康教育指导前后患者运动依从性影响因素。结果 NDDM组患者运动依从性量表评分为(78.4±3.3)分,高于DDM组的(52.7±4.1)分;重度抑郁患者较轻度抑郁患者运动治疗依从性明显降低;两组患者个体化健康教育后运动依从性量表评分较教育前均提高,差异均有统计学意义(P<0.01)。不同运动依从性的糖尿病患者性别、婚姻状况、文化程度、家庭支持、医患关系、并发症数量、住院次数、BMI、HbA1c比较差异有统计学意义(P<0.05)。结论抑郁症对糖尿病患者的运动依从性有明显影响,且抑郁程度越重运动依从性越差。个体化健康教育能有效改善糖尿病并发抑郁症患者的运动依从性,值得临床进一步研究。